{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:48:04Z","timestamp":1790171284091,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","redjournal.org","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ijrobp.2017.11.041","type":"journal-article","created":{"date-parts":[[2017,12,5]],"date-time":"2017-12-05T22:46:54Z","timestamp":1512514014000},"page":"916-925","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":285,"title":["Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma"],"prefix":"10.1016","volume":"100","author":[{"given":"Linda","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Douglass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Kleinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobu","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel E.","family":"Marciscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Forde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Brahmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan","family":"Lipson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Sharfman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chetan","family":"Bettegowda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin J.","family":"Redmond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2017.11.041_bib1","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1093\/neuonc\/nox077","article-title":"Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: A population-based study","volume":"19","author":"Cagney","year":"2017","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib2","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1200\/JCO.2004.12.149","article-title":"Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit cancer Surveillance system","volume":"22","author":"Barnholtz-Sloan","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib3","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3171\/jns.1998.88.1.0011","article-title":"Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma","volume":"88","author":"Sampson","year":"1998","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib4","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/1097-0142(19880501)61:9<1926::AID-CNCR2820610934>3.0.CO;2-I","article-title":"Central nervous system involvement in malignant melanoma","volume":"61","author":"Retsas","year":"1988","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib5","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/cam4.140","article-title":"Ipilimumab and radiation therapy for melanoma brain metastases","volume":"2","author":"Silk","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib6","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.currproblcancer.2011.07.003","article-title":"Melanoma brain metastases: Is it time to reassess the bias?","volume":"35","author":"Flanigan","year":"2011","journal-title":"Curr Probl Cancer"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib7","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejca.2016.12.017","article-title":"The majority of patients with metastatic melanoma are not represented in pivotal phase III immunotherapy trials","volume":"74","author":"Donia","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib8","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.ijrobp.2016.01.054","article-title":"Stereotactic radiosurgery: Treatment of brain metastasis without interruption of systemic therapy","volume":"95","author":"Shen","year":"2016","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib9","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","article-title":"Radiation and checkpoint blockade immunotherapy: Radiosensitisation and potential mechanisms of synergy","volume":"16","author":"Sharabi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib10","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib12","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-Year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib13","doi-asserted-by":"crossref","first-page":"5666","DOI":"10.1158\/1078-0432.CCR-16-0663","article-title":"FDA approval summary: Accelerated approval of pembrolizumab for second-line treatment of metastatic melanoma","volume":"23","author":"Chuk","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib14","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib15","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib16","doi-asserted-by":"crossref","first-page":"2980","DOI":"10.1200\/JCO.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Gettinger","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib17","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib18","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2014.58.1041","article-title":"Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab","volume":"33","author":"McDermott","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib21","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib22","first-page":"21","article-title":"The inflammatory microenvironment in brain metastases: Potential treatment target?","volume":"4","author":"Berghoff","year":"2015","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib23","doi-asserted-by":"crossref","first-page":"e1057388","DOI":"10.1080\/2162402X.2015.1057388","article-title":"Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases","volume":"5","author":"Berghoff","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/ncponc1183","article-title":"CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS","volume":"5","author":"Hodi","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40425-016-0117-1","article-title":"Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors\u2014an autopsy study","volume":"4","author":"Koelzer","year":"2016","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib26","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/CMR.0b013e3283364a37","article-title":"Complete regression of a previously untreated melanoma brain metastasis with ipilimumab","volume":"20","author":"Schartz","year":"2010","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib27","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","article-title":"Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: Early analysis of a non-randomised, open-label, phase 2 trial","volume":"17","author":"Goldberg","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib28","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","article-title":"Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial","volume":"13","author":"Margolin","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib29","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","article-title":"Role of local radiation therapy in cancer immunotherapy","volume":"1","author":"Demaria","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib30","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/PPO.0000000000000236","article-title":"Radiotherapy and immune checkpoint blockade for melanoma: A promising combinatorial strategy in need of further investigation","volume":"23","author":"Escorcia","year":"2017","journal-title":"Cancer J"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib31","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ijrobp.2017.02.031","article-title":"Use of stereotactic radiosurgery in elderly and very elderly patients with brain metastases to limit toxicity associated with whole brain radiation therapy","volume":"98","author":"Chen","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib32","first-page":"1474","article-title":"Outcomes targeting the PD-1\/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases","volume":"6","author":"Ahmed","year":"2017","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib33","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3171\/2012.5.JNS111929","article-title":"Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival","volume":"117","author":"Knisely","year":"2012","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib34","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.radonc.2017.08.009","article-title":"Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control","volume":"125","author":"An","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1097\/CMR.0b013e32835f3d90","article-title":"Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery","volume":"23","author":"Mathew","year":"2013","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib36","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/COC.0000000000000199","article-title":"Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases","volume":"40","author":"Patel","year":"2017","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib37","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3171\/2015.6.JNS142763","article-title":"Does immunotherapy increase the rate of radiation necrosis after radiosurgical treatment of brain metastases?","volume":"125","author":"Colaco","year":"2016","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib38","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-015-0095-8","article-title":"Ipilmumab and cranial radiation in metastatic melanoma patients: A case series and review","volume":"3","author":"Schoenfeld","year":"2015","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib39","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.ijrobp.2015.01.004","article-title":"Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: Safety profile and efficacy of combined treatment","volume":"92","author":"Kiess","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib40","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nature14292","article-title":"Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer","volume":"520","author":"Twyman-Saint Victor","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib41","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.1016\/S1470-2045(16)30501-0","article-title":"Ipilimumab prolongs survival in advanced melanoma","volume":"17","author":"Burki","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib42","first-page":"20","article-title":"Mechanistic considerations for the use of monoclonal antibodies for cancer therapy","volume":"11","author":"Glassman","year":"2014","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib43","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1078-0432.CCR-16-1432","article-title":"Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T cells","volume":"23","author":"Tang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib44","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1093\/jnci\/djq310","article-title":"Improved endpoints for cancer immunotherapy trials","volume":"102","author":"Hoos","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/PPO.0000000000000243","article-title":"Clinical trial design and endpoints for stage IV melanoma in the modern era","volume":"23","author":"Izar","year":"2017","journal-title":"Cancer J"},{"key":"10.1016\/j.ijrobp.2017.11.041_bib46","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1097\/JTO.0000000000000587","article-title":"Central nervous system pseudoprogression in a patient treated with PD-1 checkpoint inhibitor","volume":"10","author":"Doherty","year":"2015","journal-title":"J Thorac Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617341676?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301617341676?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T19:10:12Z","timestamp":1656443412000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301617341676"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":46,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S0360301617341676"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.11.041","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2017.11.041","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}